This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
A long-awaited draft regulation from the EU Commission’s DG Sante to deregulate the authorisation, risk assessment and labelling of a whole range of new genetically modified organisms (GMOs) has been […]
Dutch venture builder NLC has announced a 20m first close for its new Health Impact Fund, from which it will invest in 40 startups, both new investments and follow-on. It’s […]
Carthera, a Sorbonne spin-off and developer of an innovative ultrasound-based medical device for the treatment of a wide range of brain disorders, today announced the successful completion of its 37.5m […]
Donaldson Company, Inc. (NYSE: DCI), a heritage provider of innovative filtration products and solutions, announced the acquisition of Univercells Technologies (Belgium), a global provider of innovative biomanufacturing solutions for cell […]
French AI-powered radiography diagnostics specialist Gleamer SAS has raises 27m in Series B round to expand its portfolio and accelerate its expansion.
Multi-omics diagnostics specialist Centogene NV has received 30m to form a joint venture with PIF-owned pharmaceutical company Lifera in Saudi-Arabia.
French cell and gene therapy manufacturing specialist Astraveus SAS had raises 16.5m in seed money to advance its automated, microfluidic Cell and Gene Therapy manufacturing platform.
Breaking news from biotechnology and the German stock market are in the focus of the new issue of BIOTECH Insight, the newsletter of Deutsche Börse AG.
Santhera Pharmaceuticals Holding has exclusively granted the rights to commercialise its Duchenne muscular dystrophy drug vamorolone in North America to Catalyst Pharmaceuticals Inc.
BioSenic SA has suspended its Phase II proof-of-concept trial on fracture healing with its allogeneic cell therapy ALLOB.